HER2+ Breast Cancer | Specialty

Endocrine Resistance in HR+ Metastatic Breast Cancer

June 16th 2017

Emerging CDK4/6-Targeted Therapy for Breast Cancer

June 16th 2017

Choosing Therapy for HR+ Metastatic Breast Cancer

June 16th 2017

CDK4/6 Inhibitors for HR+ Metastatic Breast Cancer

June 16th 2017

FDA Approval of Ribociclib for Metastatic Breast Cancer

June 16th 2017

Dr. Freedman Discusses CNS Metastases in HER2+ Breast Cancer

June 15th 2017

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses brain metastases in patients with HER2-positive breast cancer.

Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer

June 2nd 2017

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses treatment options for patients with HER2-positive breast cancer.

FDA Panel Supports Neratinib Approval for HER2+ Breast Cancer

May 24th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 12-4 recommending approval of neratinib (Nerlynx) for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab.

Weaving Through the Landscape of HER2-Positive Breast Cancer

May 23rd 2017

Adam M. Brufsky, MD, PhD, discusses neratinib, overcoming resistance to HER2-targeted therapy, and the impact of newer agents in HER2-positive breast cancer.

Pyrotinib Shows Early Promise in HER2+ Breast Cancer

May 23rd 2017

In phase I results from China published in the Journal of Clinical Oncology, oral pyrotinib (HTI-1001) was well-tolerated and showed antitumor activity in women with HER2-positive breast cancer.

Dr. Brufsky Discusses Resistance to HER2-Targeted Therapies

May 23rd 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses resistance to HER2-targeted therapy in breast cancer.

O'Regan Covers Scope of ER+ and HER2+ Breast Cancer Advancements

May 22nd 2017

Ruth O’Regan, MD, provides insight on the evolving landscapes of ER-positive and HER2-positive breast cancers, and what regimens remain solid approaches for effective patient outcomes.

Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer

May 16th 2017

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

Expert Weighs In on Neratinib Ahead of FDA Panel Review

May 9th 2017

Wolfgang Janni, MD, PhD, discusses toxicity management with neratinib and other agents for HER2-positive breast cancer, as well as emerging treatments and impactful trials in the field.

Tripathy Highlights Neoadjuvant Advances in HER2+ Breast Cancer

May 3rd 2017

Debu Tripathy, MD, discusses current and emerging treatment strategies in the neoadjuvant setting for patients with HER2-postive breast cancer.

HER2+ Breast Cancer Heterogeneity Calls for Combos

May 2nd 2017

Targeted therapies have improved outcomes for HER2-positive breast cancer, which is characterized by an aggressive tumor phenotype and lower overall survival. However, questions remain on how to predict which patients will benefit from neoadjuvant or extended HER2-targeted therapies and how to treat patients with triple-positive breast cancer.

Dr. Janni on the Future of Treatments for HER2-Positive Breast Cancer

May 2nd 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses the future of treatments for patients with HER2-positive breast cancer.

Future Research Efforts for ALK-Driven Lung Cancer

April 27th 2017

Next Generation ALK Inhibitors for NSCLC

April 27th 2017

Treatment of ALK-Driven Refractory NSCLC

April 27th 2017